A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.

Joseph M TuscanoEmanual MaverakisSusan GroshenDenice Tsao-WeiGuilluame LuxardiAlexander A MerleevAnne BeavenJohn F DiPersioLeslie PopplewellRobert ChenMark KirschbaumMark G FrattiniEdward M Newman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

The combination of R+I has manageable toxicity and encouraging efficacy in R/R follicular lymphoma. The ratio of CD45RA-Tregs to total Tregs, and peripheral BCD should be studied further as potential predictors of response.

Keyphrases

diffuse large b cell lymphoma
hodgkin lymphoma
acute lymphoblastic leukemia
rheumatoid arthritis
acute myeloid leukemia
oxidative stress
systemic lupus erythematosus
nk cells
interstitial lung disease
climate change
systemic sclerosis
chronic lymphocytic leukemia
idiopathic pulmonary fibrosis